PIK3CD and immunodeficiency disease: In the final PPK model of sirolimus from pediatric patients with PIK3CD mutation-related immunodeficiency disease, body weight and concomitant use of posaconazole were included, where, under the same weight; the clearances of sirolimus were 1 : 0.238 between children without posaconazole and children with posaconazole.